Evidence map›Paper›PMID 33730753›Full record

GuidelineJournal of Crohn's & colitis2021

ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.

T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye and 15 more

RetractedErratum issued Registry-linked trialOpen access · bronzeAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Journal of Crohn's & colitis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. It is linked to trial NCT05452187 (Evaluation of the Safety and Effectiveness of Direct-acting Antiviral Drugs in the Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease), which is not on this map. Cited by 243 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
243citing papers in PubMed, 5 pooled it
45.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05452187 completednot on this map

Evaluation of the Safety and Effectiveness of Direct-acting Antiviral Drugs in the Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease: National Multicenter Study (MIC Project).

TypeobservationalSponsorHospital Mutua de TerrassaRan2021 to 2021Enrolled79ConditionsInflammatory Bowel Diseases, Hepatitis C Virus InfectionArmsAssess the effectiveness and safety of DAAs in patients with IBD., Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics., Assessment of the impact of DAAs on the course of IBD.
3 · Its place in the literature

Who cites it

243 citing papers in PubMed, 5 syntheses or guidelines pooled it, 431 citations in OpenAlex.

  1. Hepatitis B Virus Reactivation Risk With IL-17, IL-23/IL-12, or JAK Inhibitors: A Systematic Review and Meta-Analysis.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. The Gut Mycobiome in Inflammatory Bowel Disease: ReframingJournal of fungi (Basel, Switzerland) · 2026
    Review
  13. The Burden of Viral Respiratory Infections in Immunosuppressed Inflammatory Bowel Disease Patients.JGH open : an open access journal of gastroenterology and hepatology · 2026
    Article
  14. Observational
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Clinical Approaches toJournal of Korean medical science · 2026
    Article

183 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Expression of concern · 2022-01-24Civil Proceedings · Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Legal Reasons and/or Threats · · See also: https://doi.org/10.1093/ecco-jcc/jjab225 Journal was previously published by Elsevier until 2015.
  • Commented on by
  • Erratum issued
5 · Who and what money

Authors and funding

25 authors at 20 institutions in 15 countries.

T KucharzikDepartment of Gastroenterology, Klinikum Lüneburg, University of Hamburg, Lüneburg, Germany.
P EllulDepartment of Medicine, Division of Gastroenterology, Mater Dei Hospital, Msida, Malta.
T GreuterUniversity Hospital Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland, and Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois CHUV, University Hospital Lausanne, Lausanne, Switzerland.
J F RahierDepartment of Gastroenterology and Hepatology, CHU UCL Namur, Yvoir, Belgium.
B VerstocktDepartment of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium, and Department of Chronic Diseases, Metabolism and Ageing, TARGID-IBD, KU Leuven, Leuven, Belgium.ORCID 0000-0003-3898-7093
C AbreuInfectious Diseases Service, Centro Hospitalar Universitário São João, Porto, Portugal.
A AlbuquerqueGastroenterology Department, St James University Hospital, Leeds, UK.
M AlloccaHumanitas Clinical and Research Center - IRCCS -, Rozzano [Mi], Italy.
M EsteveHospital Universitari Mútua Terrassa, Digestive Diseases Department, Terrassa, Catalonia, and Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas CIBERehd, Madrid, Spain.
F A FarrayeInflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
H GordonDepartment of Gastroenterology, Barts Health NHS Trust, Royal London Hospital, London, UK.
K KarmirisDepartment of Gastroenterology, Venizeleio General Hospital, Heraklion, Greece.
U KopylovDepartment of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
J KirchgesnerSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France.
E MacMahonDepartment of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
F MagroGastroenterology Department, Centro Hospitalar São João, Porto, Portugal.ORCID 0000-0003-2634-9668
C MaaserOutpatient Department of Gastroenterology, Department of Geriatrics, Klinikum Lüneburg, University of Hamburg, Lüneburg, Germany.
L de RidderDepartment of Paediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
C TaxoneraIBD Unit, Department of Gastroenterology, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos [IdISSC], Madrid, Spain.ORCID 0000-0001-9166-7350
M TorunerAnkara University School of Medicine, Department of Gastroenterology, Ankara, Turkey.
L TremblayCentre Hospitalier de l'Université de Montréal [CHUM] Pharmacy Department and Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada.
M ScharlUniversity Hospital Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland.
N VigetDepartment of Infectious Diseases, Tourcoing Hospital, Tourcoing, France.
Y ZabanaHospital Universitari Mútua Terrassa, Digestive Diseases Department, Terrassa, Catalonia, and Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas CIBERehd, Madrid, Spain.
S VavrickaUniversity Hospital Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland.
Universität Hamburg · DEUniversity Hospital Mútua de Terrassa · ESUniversity Hospital of Zurich · CHAnkara University · TRBarts Health NHS Trust · GBCentre Hospitalier de l’Université de Montréal · CACentre Hospitalier de Tourcoing · FRCHU Dinant Godinne UCL Namur · BEErasmus MC - Sophia Children’s Hospital · NLGuy's and St Thomas' NHS Foundation Trust · GBHospital Clínico San Carlos · ESHospital de São João · PTHumanitas University · ITInserm · FRKU Leuven · BEMater Dei Hospital · MTSt James's University Hospital · GBTel Aviv University · ILThe General Hospital of Heraklion "Venizeleio-Pananio" · GRUniversidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunocompromised HostHumansImmunosuppressive AgentsInflammatory Bowel DiseasesOpportunistic InfectionsVaccinationImmunosuppressive AgentsECCO guidelinesinflammatory bowel diseaseOpportunistic infectionsvaccination

Identifiers

PMID33730753
OpenAlexW3137785750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.